Individualised Homoeopathic Treatment of Chronic Brucellosis in human beings along with Standard Care – An open-label, pragmatic, and two arm Pilot Study

Brucellosis, classified among the "seven neglected endemic zoonoses" by the World Health Organization (WHO), continues to pose significant health concerns, particularly in regions like Western Asia, the Middle East, the Mediterranean, and Central and South America. Despite progress in control efforts, its persistence in areas like Peru, Kuwait, and Saudi Arabia underscores the need for ongoing monitoring and interventions. Brucellosis, caused by Brucella sp., not only affects animals but also poses financial burdens on affected individuals due to hospital care, pharmacotherapy, and lost income from sick leave.

The clinical manifestations of Brucellosis encompass fever, sweats, fatigue, anorexia, headache, arthralgia, and back pain. Recognizing these symptoms, exceedingly prolonged fever without an evident cause is crucial for early diagnosis.

While the mortality rate is low, timely diagnosis and therapy are critical, particularly in cases of endocarditis or central nervous system involvement. Focal disease cases may require intensive therapeutic approaches, including surgical intervention and extended antibiotic therapy.

Research into combining homoeopathic treatments with allopathic standard care for Brucellosis may yield valuable evidence. Well-designed clinical studies can establish a robust body of evidence, enhancing our understanding and management of the disease. This integrated approach evaluates the ADD-ON effects of homoeopathic remedies alongside established allopathic protocols, which may contribute to evidence-based healthcare practices. The ultimate goal is to improve treatment strategies for Brucellosis, offering clinicians more comprehensive options and benefiting patients by potentially enhancing outcomes and quality of life. This research aligns with a commitment to delivering the best care through an evidence-backed, integrative approach.